The Role of Intravenous Selexipag in Managing PAH and Bridging Gaps in Oral Treatment: A Narrative Review
Sienna Goren,1,* Nermeen Kidwai,1,* Wilbert S Aronow,2 Gregg M Lanier2 1New York Medical College, Valhalla, NY, USA; 2Departments of Medicine and Cardiology, Westchester Medical Center and New York Medical College, Valhalla, NY, USA*These authors contributed equally to this workCorrespondence: Wilbe...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2025-01-01
|
| Series: | Therapeutics and Clinical Risk Management |
| Subjects: | |
| Online Access: | https://www.dovepress.com/the-role-of-intravenous-selexipag-in-managing-pah-and-bridging-gaps-in-peer-reviewed-fulltext-article-TCRM |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1841544156389834752 |
|---|---|
| author | Goren S Kidwai N Aronow WS Lanier GM |
| author_facet | Goren S Kidwai N Aronow WS Lanier GM |
| author_sort | Goren S |
| collection | DOAJ |
| description | Sienna Goren,1,* Nermeen Kidwai,1,* Wilbert S Aronow,2 Gregg M Lanier2 1New York Medical College, Valhalla, NY, USA; 2Departments of Medicine and Cardiology, Westchester Medical Center and New York Medical College, Valhalla, NY, USA*These authors contributed equally to this workCorrespondence: Wilbert S Aronow, Department of Cardiology, Westchester Medical Center, and Professor of Medicine, New York Medical College, Macy Pavilion, Room 141, Valhalla, NY, 10595, USA, Tel +1 914 493 5311, Fax +1 914 235 6274, Email Wilbert.Aronow@wmchealth.orgAbstract: Pulmonary arterial hypertension (PAH) is a rare and potentially fatal condition characterized by progressive increases in blood pressure in the arteries of the lungs. Oral selexipag, approved by the Food and Drug Administration (FDA) in 2015 for the treatment of PAH, targets prostacyclin receptors on pulmonary arterial vascular smooth muscle and endothelial cells to improve blood flow through the lungs and reduce pulmonary vascular resistance. Oral selexipag is effective, but may be discontinued due to factors like side effects, emergency conditions, or inability to take oral medication, potentially leading to severe adverse events, such as rebound pulmonary hypertension and right heart failure. To address treatment interruptions, intravenous (IV) selexipag was introduced as an alternative for patients who are temporarily unable to take oral medications. IV selexipag bypasses hepatic metabolism, requiring a 12.5% higher dose compared to the oral form to achieve similar therapeutic effects. It is administered via IV infusion twice daily over 80 minutes, typically for short-term use. However, caution is needed when prescribing selexipag to patients with hepatic or renal issues, and it is contraindicated with strong CYP2C8 inhibitors. A Phase III clinical trial confirmed that switching between oral and IV selexipag was safe, with comparable efficacy and tolerability, though it was limited by small sample size and short duration. Given the risks of treatment interruption and the complexity of managing PAH, this review provides essential insights into the practical use of IV selexipag as a bridging therapy. Furthermore, it calls for larger clinical trials to refine dosing strategies, explore long-term outcomes, and identify patient populations most likely to benefit from IV selexipag.Plain Language Summary: Pulmonary arterial hypertension (PAH) is a rare and dangerous condition that causes high blood pressure in the arteries of the lungs, leading to right heart failure and potentially death. Selexipag is a medication used to treat patients with PAH by widening the blood vessels in the lungs. However, some patients may not be able to take oral selexipag as prescribed, which can worsen their condition. In 2021, an intravenous (IV) form of selexipag was approved as a temporary alternative for these patients. This review examines available literature to provide background and practical instruction for providers prescribing IV selexipag.Unlike oral selexipag, which is processed by enzymes in the liver, the IV form bypasses liver metabolism and enters the bloodstream directly. As a result, the IV dose is typically 12.5% higher than the oral dose to achieve the same therapeutic effects. IV selexipag is administered twice daily through an infusion lasting about 80 minutes and is intended for temporary use. Healthcare providers should use caution when prescribing selexipag to patients with liver or kidney issues. Additionally, selexipag should not be used with medications that block CYP enzymes. A phase III clinical trial reports that common side effects of the IV form of selexipag include headaches and irritation at the injection site. While IV selexipag is considered safe and effective for short-term use, larger studies are needed to better understand how to manage transitions between oral and IV forms.Keywords: prostacyclin, right heart failure, treatment interruption, intravenous selexipag, IP agonist |
| format | Article |
| id | doaj-art-ba5ab9cee10841f5bc7f5205af5633d0 |
| institution | Kabale University |
| issn | 1178-203X |
| language | English |
| publishDate | 2025-01-01 |
| publisher | Dove Medical Press |
| record_format | Article |
| series | Therapeutics and Clinical Risk Management |
| spelling | doaj-art-ba5ab9cee10841f5bc7f5205af5633d02025-01-12T16:52:42ZengDove Medical PressTherapeutics and Clinical Risk Management1178-203X2025-01-01Volume 21556099136The Role of Intravenous Selexipag in Managing PAH and Bridging Gaps in Oral Treatment: A Narrative ReviewGoren SKidwai NAronow WSLanier GMSienna Goren,1,* Nermeen Kidwai,1,* Wilbert S Aronow,2 Gregg M Lanier2 1New York Medical College, Valhalla, NY, USA; 2Departments of Medicine and Cardiology, Westchester Medical Center and New York Medical College, Valhalla, NY, USA*These authors contributed equally to this workCorrespondence: Wilbert S Aronow, Department of Cardiology, Westchester Medical Center, and Professor of Medicine, New York Medical College, Macy Pavilion, Room 141, Valhalla, NY, 10595, USA, Tel +1 914 493 5311, Fax +1 914 235 6274, Email Wilbert.Aronow@wmchealth.orgAbstract: Pulmonary arterial hypertension (PAH) is a rare and potentially fatal condition characterized by progressive increases in blood pressure in the arteries of the lungs. Oral selexipag, approved by the Food and Drug Administration (FDA) in 2015 for the treatment of PAH, targets prostacyclin receptors on pulmonary arterial vascular smooth muscle and endothelial cells to improve blood flow through the lungs and reduce pulmonary vascular resistance. Oral selexipag is effective, but may be discontinued due to factors like side effects, emergency conditions, or inability to take oral medication, potentially leading to severe adverse events, such as rebound pulmonary hypertension and right heart failure. To address treatment interruptions, intravenous (IV) selexipag was introduced as an alternative for patients who are temporarily unable to take oral medications. IV selexipag bypasses hepatic metabolism, requiring a 12.5% higher dose compared to the oral form to achieve similar therapeutic effects. It is administered via IV infusion twice daily over 80 minutes, typically for short-term use. However, caution is needed when prescribing selexipag to patients with hepatic or renal issues, and it is contraindicated with strong CYP2C8 inhibitors. A Phase III clinical trial confirmed that switching between oral and IV selexipag was safe, with comparable efficacy and tolerability, though it was limited by small sample size and short duration. Given the risks of treatment interruption and the complexity of managing PAH, this review provides essential insights into the practical use of IV selexipag as a bridging therapy. Furthermore, it calls for larger clinical trials to refine dosing strategies, explore long-term outcomes, and identify patient populations most likely to benefit from IV selexipag.Plain Language Summary: Pulmonary arterial hypertension (PAH) is a rare and dangerous condition that causes high blood pressure in the arteries of the lungs, leading to right heart failure and potentially death. Selexipag is a medication used to treat patients with PAH by widening the blood vessels in the lungs. However, some patients may not be able to take oral selexipag as prescribed, which can worsen their condition. In 2021, an intravenous (IV) form of selexipag was approved as a temporary alternative for these patients. This review examines available literature to provide background and practical instruction for providers prescribing IV selexipag.Unlike oral selexipag, which is processed by enzymes in the liver, the IV form bypasses liver metabolism and enters the bloodstream directly. As a result, the IV dose is typically 12.5% higher than the oral dose to achieve the same therapeutic effects. IV selexipag is administered twice daily through an infusion lasting about 80 minutes and is intended for temporary use. Healthcare providers should use caution when prescribing selexipag to patients with liver or kidney issues. Additionally, selexipag should not be used with medications that block CYP enzymes. A phase III clinical trial reports that common side effects of the IV form of selexipag include headaches and irritation at the injection site. While IV selexipag is considered safe and effective for short-term use, larger studies are needed to better understand how to manage transitions between oral and IV forms.Keywords: prostacyclin, right heart failure, treatment interruption, intravenous selexipag, IP agonisthttps://www.dovepress.com/the-role-of-intravenous-selexipag-in-managing-pah-and-bridging-gaps-in-peer-reviewed-fulltext-article-TCRMprostacyclinright heart failuretreatment interruptionintravenous selexipagip agonist |
| spellingShingle | Goren S Kidwai N Aronow WS Lanier GM The Role of Intravenous Selexipag in Managing PAH and Bridging Gaps in Oral Treatment: A Narrative Review Therapeutics and Clinical Risk Management prostacyclin right heart failure treatment interruption intravenous selexipag ip agonist |
| title | The Role of Intravenous Selexipag in Managing PAH and Bridging Gaps in Oral Treatment: A Narrative Review |
| title_full | The Role of Intravenous Selexipag in Managing PAH and Bridging Gaps in Oral Treatment: A Narrative Review |
| title_fullStr | The Role of Intravenous Selexipag in Managing PAH and Bridging Gaps in Oral Treatment: A Narrative Review |
| title_full_unstemmed | The Role of Intravenous Selexipag in Managing PAH and Bridging Gaps in Oral Treatment: A Narrative Review |
| title_short | The Role of Intravenous Selexipag in Managing PAH and Bridging Gaps in Oral Treatment: A Narrative Review |
| title_sort | role of intravenous selexipag in managing pah and bridging gaps in oral treatment a narrative review |
| topic | prostacyclin right heart failure treatment interruption intravenous selexipag ip agonist |
| url | https://www.dovepress.com/the-role-of-intravenous-selexipag-in-managing-pah-and-bridging-gaps-in-peer-reviewed-fulltext-article-TCRM |
| work_keys_str_mv | AT gorens theroleofintravenousselexipaginmanagingpahandbridginggapsinoraltreatmentanarrativereview AT kidwain theroleofintravenousselexipaginmanagingpahandbridginggapsinoraltreatmentanarrativereview AT aronowws theroleofintravenousselexipaginmanagingpahandbridginggapsinoraltreatmentanarrativereview AT laniergm theroleofintravenousselexipaginmanagingpahandbridginggapsinoraltreatmentanarrativereview AT gorens roleofintravenousselexipaginmanagingpahandbridginggapsinoraltreatmentanarrativereview AT kidwain roleofintravenousselexipaginmanagingpahandbridginggapsinoraltreatmentanarrativereview AT aronowws roleofintravenousselexipaginmanagingpahandbridginggapsinoraltreatmentanarrativereview AT laniergm roleofintravenousselexipaginmanagingpahandbridginggapsinoraltreatmentanarrativereview |